Cerus Corporation (CERS) - Total Liabilities
Based on the latest financial reports, Cerus Corporation (CERS) has total liabilities worth $154.62 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Cerus Corporation (CERS) equity growth momentum to track the company's year-over-year net asset growth rate.
Cerus Corporation - Total Liabilities Trend (1997–2025)
This chart illustrates how Cerus Corporation's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Cerus Corporation to measure how efficiently the company converts operating cash flow to free cash.
Cerus Corporation Competitors by Total Liabilities
The table below lists competitors of Cerus Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EVS Broadcast Equipment SA
BR:EVS
|
Belgium | €66.59 Million |
|
Guangdong Ganhua Science & Industry Co Ltd
SHE:000576
|
China | CN¥679.59 Million |
|
C&C Group PLC
F:GCC
|
Germany | €787.20 Million |
|
Yonker Environmental Protect
SHE:300187
|
China | CN¥2.42 Billion |
|
Harson Trading China Co Ltd
SHG:603958
|
China | CN¥940.35 Million |
|
Better Home & Finance Holding Company
NYSE:BETR
|
USA | $1.16 Billion |
|
Design Therapeutics Inc
NASDAQ:DSGN
|
USA | $12.05 Million |
|
D&O Home Collection Co Ltd
SHE:002798
|
China | CN¥3.05 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Cerus Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CERS market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cerus Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cerus Corporation (1997–2025)
The table below shows the annual total liabilities of Cerus Corporation from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $156.89 Million | +8.94% |
| 2024-12-31 | $144.02 Million | -0.20% |
| 2023-12-31 | $144.30 Million | -3.49% |
| 2022-12-31 | $149.53 Million | -1.55% |
| 2021-12-31 | $151.88 Million | +29.14% |
| 2020-12-31 | $117.61 Million | +8.41% |
| 2019-12-31 | $108.48 Million | +37.42% |
| 2018-12-31 | $78.94 Million | +33.11% |
| 2017-12-31 | $59.30 Million | +29.80% |
| 2016-12-31 | $45.69 Million | +2.20% |
| 2015-12-31 | $44.70 Million | +11.59% |
| 2014-12-31 | $40.06 Million | -1.29% |
| 2013-12-31 | $40.59 Million | +36.14% |
| 2012-12-31 | $29.81 Million | +10.19% |
| 2011-12-31 | $27.05 Million | +10.72% |
| 2010-12-31 | $24.43 Million | +87.34% |
| 2009-12-31 | $13.04 Million | -0.14% |
| 2008-12-31 | $13.06 Million | -28.71% |
| 2007-12-31 | $18.32 Million | +23.41% |
| 2006-12-31 | $14.85 Million | -36.51% |
| 2005-12-31 | $23.39 Million | -70.98% |
| 2004-12-31 | $80.59 Million | +22.22% |
| 2003-12-31 | $65.94 Million | +292.98% |
| 2002-12-31 | $16.78 Million | -21.98% |
| 2001-12-31 | $21.50 Million | +75.69% |
| 2000-12-31 | $12.24 Million | +39.09% |
| 1999-12-31 | $8.80 Million | -55.10% |
| 1998-12-31 | $19.60 Million | +308.33% |
| 1997-12-31 | $4.80 Million | -- |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more